🇺🇸 FDA
Patent

US 10160736

1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators

granted A61KA61K31/4245A61K31/433

Quick answer

US patent 10160736 (1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators) held by Aurigene Discovery Technologies Limited expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aurigene Discovery Technologies Limited
Grant date
Tue Dec 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/4245, A61K31/433, A61K45/06, A61P